Agios Pharmaceuticals boosts mitapivat revenue as U.S. prescriptions climb
Worldwide net revenues for mitapivat rose to $44.7 million in the second quarter of 2026.
Agios Pharmaceuticals (AGIO) reported a significant increase in revenue from its drug mitapivat for the second quarter ended June 30, 2026. The biotechnology company saw a sharp rise in commercial adoption of the therapy, particularly within the United States.
Worldwide net revenues for mitapivat rose to $44.7 million in the second quarter of 2026, compared to $12.5 million in the same period a year earlier. This growth was driven largely by the U.S. market, where net revenue grew sequentially from $18.8 million in the first quarter to $40.9 million in the second quarter. Ex-U.S. net revenue also increased sequentially, rising from $1.9 million to $3.8 million.
The revenue trajectory was driven by an increase in patient volume. Cumulative AQVESME prescriptions for thalassemia in the U.S. rose to 442 as of June 30, 2026, from 242 as of March 31, 2026.
Net loss for the quarter narrowed to $100.7 million, compared to a loss of $112.0 million in the second quarter of 2025. Operating expenses increased during the period, with research and development costs rising to $100.8 million from $91.9 million a year ago. The R&D increase was primarily due to a $25.0 million up-front payment for the licensing of cevidoplenib.
Selling, general and administrative expenses rose to $51.5 million from $45.9 million in the prior-year quarter due to the U.S. commercial launch of AQVESME. Cash, cash equivalents, and marketable securities totaled $964.8 million as of June 30, 2026, down from $1.2 billion as of December 31, 2025.
Agios shifted its clinical focus by discontinuing the development of tebapivat in sickle cell disease and lower-risk myelodysplastic syndromes following Phase 2 results. To expand its pipeline, the company licensed cevidoplenib for immune thrombocytopenia and advanced AG-236 into Phase 2/3 development for polycythemia vera.
The company is awaiting a regulatory decision on the mitapivat supplemental New Drug Application in sickle cell disease. The FDA granted Priority Review for the application, with a PDUFA goal date of November 1, 2026.